What does "for research use only" mean under EU medicines law?
A "for research use only" or "not for human consumption" label does not create a label-based exemption under Directive 2001/83/EC. The Directive asks how a product is presented. It also asks what the product may be used or administered to do.
The source is the EU's English text dated 1 January 2025, document 02001L0083-20250101 (verified 21 August 2026). The same rules appear in the EU's 2012 English text.
What scope does Directive 2001/83/EC set?
Article 2(1) sets the scope.
"This Directive shall apply to medicinal products for human use intended to be placed on the market in Member States and either prepared industrially or manufactured by a method involving an industrial process."
Source, verified 21 August 2026: Directive 2001/83/EC, Article 2(1), consolidation 02001L0083-20250101.
The product must be meant for the market in a Member State. It must either be prepared industrially or be made by an industrial process. This page does not decide those facts for any one product.
What are the two medicinal-product tests?
Article 1(2) gives two tests. The word "or" joins them.
(a) Any substance or combination of substances presented as having properties for treating or preventing disease in human beings; or
(b) Any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.
Source, verified 21 August 2026: Directive 2001/83/EC, Article 1(2), consolidation 02001L0083-20250101.
Either test can meet the definition.
| Article 1(2) limb | The text turns on | What the label does not settle |
|---|---|---|
| (a) Presentation | Whether the substance is presented as treating or preventing disease. | A label is evidence about presentation, not an automatic classification result. |
| (b) Function | What the substance may be used or administered to do through the listed actions. | Label wording does not remove this separate statutory question. |
Does the wording decide either test?
In 02001L0083-20250101, a full search found zero uses of the exact phrase "research use only" (search ignored case; verified 21 August 2026). A full search of the same text found zero uses of the exact phrase "not for human consumption" (search ignored case; verified 21 August 2026).
Those zero counts do not decide the result. Test (a) still asks how a product is presented. Test (b) still asks what the substance may be used or administered to do.
Neither phrase gives a label-based exemption in the text. A label may be evidence under the presentation test. It does not replace the function test.
What does the research exclusion cover?
Article 3, point 3 lists the excluded case.
"Medicinal products intended for research and development trials, but without prejudice to the provisions of Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use."
Source, verified 21 August 2026: Directive 2001/83/EC, Article 3, point 3, consolidation 02001L0083-20250101.
The text covers medicinal products meant for research and development trials. It does not say that label text creates an exemption.
The current text still cites Directive 2001/20/EC. Article 96 of Regulation (EU) No 536/2014 tells the reader how to read that citation.
"Directive 2001/20/EC is repealed as from the date referred to in the second paragraph of Article 99."
"References to Directive 2001/20/EC shall be construed as references to this Regulation and shall be read in accordance with the correlation table laid down in Annex VII."
Source, verified 21 August 2026: Regulation (EU) No 536/2014, Article 96, CELEX 32014R0536.
Germany's current AMG § 4(23) also says Regulation (EU) No 536/2014 repealed Directive 2001/20/EC (official text, verified 21 August 2026). This page does not cover the rules for clinical trials.
What rule applies to market placement?
Article 6(1) states the market rule.
"No medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State in accordance with this Directive or an authorisation has been granted in accordance with Regulation (EC) No 726/2004..."
Source, verified 21 August 2026: Directive 2001/83/EC, Article 6(1), consolidation 02001L0083-20250101.
Article 2(2) covers a product that may also fit another EU-law product definition.
"In cases of doubt, where, taking into account all its characteristics, a product may fall within the definition of a ‘medicinal product’ and within the definition of a product covered by other Community legislation the provisions of this Directive shall apply."
Source, verified 21 August 2026: Directive 2001/83/EC, Article 2(2), consolidation 02001L0083-20250101.
Article 2(2) requires possible fit with both definitions. It is not a general rule that every uncertainty makes a product medicinal.
Does this classify a particular peptide?
The quoted text does not name any peptide. Classifying one product requires its own facts. Those facts must be tested under Article 1(2) within Article 2.
The wording on a label does not measure the product's identity. It does not measure the product's purity. It does not measure the product's sterility. For identity, see what is in the vial. For purity, see what a certificate of analysis proves. For sterility, see sterility and infection.
See the complete peptide risk guide for related questions about vials, tests and current symptoms.